JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

Search

Guardant Health Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

109.59 -1.12

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

105.58

Max

111.55

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+8.21% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.9B

15B

Ankstesnė atidarymo kaina

110.71

Ankstesnė uždarymo kaina

109.59

Naujienos nuotaikos

By Acuity

50%

50%

133 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-28 23:51; UTC

Uždarbis

Correction to Samsung Fourth-Quarter Net Profit Article

2026-01-28 23:49; UTC

Karštos akcijos

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

2026-01-28 23:19; UTC

Uždarbis

Samsung's Fourth-Quarter Net Profit Beats Consensus

2026-01-28 22:43; UTC

Uždarbis

Waste Management Logs Higher 4Q Profit as Revenue Rises

2026-01-29 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

2026-01-29 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

2026-01-29 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

2026-01-29 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

2026-01-28 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026-01-28 23:30; UTC

Rinkos pokalbiai

Tesla to Use Car Factory for Robot Aims -- Market Talk

2026-01-28 23:28; UTC

Uždarbis

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

2026-01-28 23:26; UTC

Uždarbis

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

2026-01-28 23:21; UTC

Uždarbis

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

2026-01-28 23:18; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

2026-01-28 22:58; UTC

Uždarbis

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

2026-01-28 22:48; UTC

Rinkos pokalbiai

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

2026-01-28 22:45; UTC

Uždarbis

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

2026-01-28 22:44; UTC

Uždarbis

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

2026-01-28 22:43; UTC

Uždarbis

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

2026-01-28 22:41; UTC

Uždarbis
Karštos akcijos

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

2026-01-28 22:41; UTC

Rinkos pokalbiai

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

2026-01-28 22:41; UTC

Uždarbis

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

2026-01-28 22:40; UTC

Uždarbis

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

2026-01-28 22:39; UTC

Uždarbis

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

2026-01-28 22:38; UTC

Uždarbis

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

2026-01-28 22:37; UTC

Uždarbis

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

2026-01-28 22:35; UTC

Uždarbis

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

2026-01-28 22:26; UTC

Rinkos pokalbiai
Uždarbis

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

2026-01-28 22:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-28 22:20; UTC

Rinkos pokalbiai

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

8.21% į viršų

12 mėnesių prognozė

Vidutinis 124 USD  8.21%

Aukščiausias 140 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

133 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat